Company / PP&E (Net)
Zentalis Pharmaceuticals, Inc. PP&E (Net) History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.8M
FY2025
5-year range
$2.8M / $4.7M
FY2024-FY2025
Trend
-41.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$3M in FY2025.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, pp&e (net) decreased 41.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.8M | -41.1% |
| FY2024 | $4.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026